Akebia Therapeutics (AKBA) Faces Covid Headwinds to Beat Expectations - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $8.00 price target on Akebia Therapeutics (NASDAQ: AKBA) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
